ciclopirox and Hematologic Malignancies studies

Research Excerpts

Excerpt	Relevance	Reference
"Ciclopirox was rapidly absorbed and cleared with a short half-life."	6.79	Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies. ( Brandwein, JM; Chang, H; Goard, CA; Gronda, M; Gupta, V; Haslam, JL; Heppert, KE; Hogge, DE; Hurren, R; Jitkova, Y; Kasper, J; Minden, MD; Patton, L; Rajewski, LG; Reed, GA; Schimmer, AD; Schorno, K; Schuh, AC; Trudel, S; Webster, DA; Weir, SJ; Yee, KW, 2014)
"Ciclopirox was rapidly absorbed and cleared with a short half-life."	2.79	Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies. ( Brandwein, JM; Chang, H; Goard, CA; Gronda, M; Gupta, V; Haslam, JL; Heppert, KE; Hogge, DE; Hurren, R; Jitkova, Y; Kasper, J; Minden, MD; Patton, L; Rajewski, LG; Reed, GA; Schimmer, AD; Schorno, K; Schuh, AC; Trudel, S; Webster, DA; Weir, SJ; Yee, KW, 2014)

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Timeframe

Studies, this research(%)

All Research%

pre-1990

0 (0.00)

18.7374

1990's

0 (0.00)

18.2507

2000's

0 (0.00)

29.6817

2010's

2 (100.00)

24.3611

2020's

0 (0.00)

2.80

Authors

Authors	Studies
Minden, MD	1
Hogge, DE	1
Weir, SJ	2
Kasper, J	2
Webster, DA	1
Patton, L	2
Jitkova, Y	1
Hurren, R	1
Gronda, M	1
Goard, CA	1
Rajewski, LG	1
Haslam, JL	1
Heppert, KE	1
Schorno, K	1
Chang, H	1
Brandwein, JM	1
Gupta, V	1
Schuh, AC	1
Trudel, S	1
Yee, KW	1
Reed, GA	1
Schimmer, AD	2
Castle, K	1
Rajewski, L	1

Studies

Minden, MD

Hogge, DE

Weir, SJ

Kasper, J

Webster, DA

Patton, L

Jitkova, Y

Hurren, R

Gronda, M

Goard, CA

Rajewski, LG

Haslam, JL

Heppert, KE

Schorno, K

Chang, H

Brandwein, JM

Gupta, V

Schuh, AC

Trudel, S

Yee, KW

Reed, GA

Schimmer, AD

Castle, K

Rajewski, L

Trials

1 trial available for ciclopirox and Hematologic Malignancies

Article	Year
Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies. American journal of hematology, 2014, Volume: 89, Issue:4 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Ciclopirox; Female; Gas	2014

Article

Year

Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies.

American journal of hematology, 2014, Volume: 89, Issue:4

Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Ciclopirox; Female; Gas

2014

Other Studies

1 other study available for ciclopirox and Hematologic Malignancies

Article	Year
The repositioning of the anti-fungal agent ciclopirox olamine as a novel therapeutic agent for the treatment of haematologic malignancy. Journal of clinical pharmacy and therapeutics, 2011, Volume: 36, Issue:2 Topics: Animals; Antifungal Agents; Cell Death; Cell Line, Tumor; Ciclopirox; Clinical Trials as Topic; Derm	2011

Article

Year

The repositioning of the anti-fungal agent ciclopirox olamine as a novel therapeutic agent for the treatment of haematologic malignancy.

Journal of clinical pharmacy and therapeutics, 2011, Volume: 36, Issue:2

Topics: Animals; Antifungal Agents; Cell Death; Cell Line, Tumor; Ciclopirox; Clinical Trials as Topic; Derm

2011